A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone

Published:2018-02 Issue:2 Volume:29 Page:352-360
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wang L.,Dehm S.M.,Hillman D.W.,Sicotte H.,Tan W.,Gormley M.,Bhargava V.,Jimenez R.,Xie F.,Yin P.,Qin S.,Quevedo F.,Costello B.A.,Pitot H.C.,Ho T.,Bryce A.H.,Ye Z.,Li Y.,Eiken P.,Vedell P.T.,Barman P.,McMenomy B.P.,Atwell T.D.,Carlson R.E.,Ellingson M.,Eckloff B.W.,Qin R.,Ou F.,Hart S.N.,Huang H.,Jen J.,Wieben E.D.,Kalari K.R.,Weinshilboum R.M.,Wang L.,Kohli M.^ORCID

Funder

Department of Defense

National Institutes of Health

Prostate Cancer Foundation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/2/352/27257663/mdx689.pdf

Reference28 articles.

1. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target;Chen;Lancet Oncol,2009